Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jul 14, 2023; 29(26): 4186-4199
Published online Jul 14, 2023. doi: 10.3748/wjg.v29.i26.4186
Table 1 Clinicopathologic characteristics of patients in the training and validation cohorts
Parameter
Training cohort, n = 277Validation cohort, n = 125P value
GenderFemale40 (14.44)18 (14.40)0.991
Male237 (85.56)107 (85.60)
Age (yr)50.60 ± 11.2751.92 ± 10.500.265
HBsAgNegative45 (16.25)22 (17.60)0.736
Positive232 (83.75)103 (82.40)
Child-Pugh stageA252 (90.97)116 (92.80)0.543
B25 (9.03)9 (7.20)
BCLC stage0 + A173 (62.45)83 (66.40)0.447
B + C104 (37.55)42 (33.60)
CirrhosisAbsent22 (7.94)8 (6.40)0.586
Present255 (92.06)117 (93.60)
MVIAbsent162 (58.48)75 (60.00)0.775
Present115 (41.52)50 (40.00)
AFP (ng/mL)≤ 200130 (46.93)67 (53.60)0.204
> 200147 (53.07)58 (46.40)
Tumor size (cm)7.42 ± 4.517.07 ± 4.030.464
Platelets (× 109/L)198.26 ± 94.67201.52 ± 86.770.743
GGT (U/L, median, IQR)73.90 (41.74, 130.23)80.35 (46.92, 151.00)0.198
ALT (U/L, median, IQR)32.80 (21.11, 51.70)29.51 (20.50, 48.82)0.176
AST (U/L, median, IQR)36.47 (26.75, 53.80)35.04 (25.90, 51.60)0.449
TB (mg/dL)17.41 ± 26.5217.40 ± 23.840.995
DB (mg/dL)7.99 ± 17.548.92 ± 23.260.658
ALBI-2.50 ± 0.47-2.53 ± 0.420.493
Table 2 Univariate and multivariate Cox regression analyses of clinicopathologic characteristics for recurrence-free survival in training cohort with hepatocellular carcinoma
VariableUnivariate analysis
Multivariate analysis
HR95%CIP valueHR95%CIP value
Rad-score (high vs low) (n)4.082.64-6.24< 0.0013.862.41-6.16< 0.001
HBsAg (present vs absent) (n)1.810.97-3.390.063
Cirrhosis (present vs absent) (n)1.840.75-4.520.183
MVI (present vs absent) (n)1.831.24-2.710.0021.200.77-1.850.418
AFP (> 200 vs ≤ 200) (ng/mL)1.731.16-2.580.0071.521.00-2.300.048
Tumor size (cm)1.051.01-1.090.0051.000.94-1.040.621
Platelets (× 109/L)1.001.00-1.000.160
GGT (U/L)1.021.04-1.020.0341.011.01-1.000.333
DB (mg/dL)1.001.00-1.010.928
ALBI0.960.64-1.440.838